235 related articles for article (PubMed ID: 11002233)
21. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
22. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.
Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C
J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998
[TBL] [Abstract][Full Text] [Related]
23. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy.
Cooper DL; Caride VJ; Zloty M; Germino J; Farber LR; Hoffer PB
J Clin Oncol; 1993 Jun; 11(6):1092-8. PubMed ID: 8501495
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
[TBL] [Abstract][Full Text] [Related]
25. Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease.
Ng AK; Bernardo MV; Silver B; Van Den Abbeele A; Stevenson MA; Fisher DC; Mauch PM
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):175-84. PubMed ID: 15629609
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Hodgkin lymphoma: a 50-year perspective.
Canellos GP; Rosenberg SA; Friedberg JW; Lister TA; Devita VT
J Clin Oncol; 2014 Jan; 32(3):163-8. PubMed ID: 24441526
[No Abstract] [Full Text] [Related]
27. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
[TBL] [Abstract][Full Text] [Related]
28. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
Constine LS
J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
[No Abstract] [Full Text] [Related]
29. Pediatric stage IV Hodgkin disease. Long-term survival.
Bader SB; Weinstein H; Mauch P; Silver B; Tarbell NJ
Cancer; 1993 Jul; 72(1):249-55. PubMed ID: 7685242
[TBL] [Abstract][Full Text] [Related]
30. Ga-67 scintigraphy in patients with breast lymphoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Satoh K; Ohkawa M
Clin Nucl Med; 2002 Feb; 27(2):101-4. PubMed ID: 11786738
[TBL] [Abstract][Full Text] [Related]
31. [Controversial aspects in the current treatment of Hodgkin's disease].
Vicente J
Rev Clin Esp; 1987 Feb; 180(3):158-64. PubMed ID: 2437622
[No Abstract] [Full Text] [Related]
32. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial.
Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L
J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381
[TBL] [Abstract][Full Text] [Related]
33. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Wilder RB; Schlembach PJ; Jones D; Chronowski GM; Ha CS; Younes A; Hagemeister FB; Barista I; Cabanillas F; Cox JD
Cancer; 2002 Mar; 94(6):1731-8. PubMed ID: 11920535
[TBL] [Abstract][Full Text] [Related]
34. [Advances in the chemotherapy of malignant lymphoma 1. Chemotherapy of Hodgkin's disease].
Suon SZ
Zhonghua Nei Ke Za Zhi; 1985 Feb; 24(2):117-120, contd. PubMed ID: 2580675
[No Abstract] [Full Text] [Related]
35. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
[TBL] [Abstract][Full Text] [Related]
36. Development of pulmonary histiocytosis X after chemotherapy for Hodgkin disease.
Shanley DJ; Lerud KS; Luetkehans TJ
AJR Am J Roentgenol; 1990 Oct; 155(4):741-2. PubMed ID: 1698017
[No Abstract] [Full Text] [Related]
37. ABVD versus MOPP: which is better?
Rosenberg SA
J Clin Oncol; 1987 Jan; 5(1):7. PubMed ID: 2433410
[No Abstract] [Full Text] [Related]
38. Long-term follow-up of survival in Hodgkin's lymphoma.
Canellos GP; Niedzwiecki D; Johnson JL
N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
[No Abstract] [Full Text] [Related]
39. [Rescue treatment in Hodgkin's disease].
Zori Comba A; Koziner B
Sangre (Barc); 1987; 32(1):67-76. PubMed ID: 2438788
[No Abstract] [Full Text] [Related]
40. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
